Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D3GIQ9
|
|||
| Drug Name |
JNJ-67856633
|
|||
| Indication | Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 1 | [1] | |
| Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C82-C85; ICD-9: 200, 202] | Phase 1 | [1] | ||
| Company |
Janssen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | MALT lymphoma-associated translocation (MALT1) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03900598) A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). U.S. National Institutes of Health. | |||
| REF 2 | National Cancer Institute Drug Dictionary (drug name JNJ67856633). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.